

Olivier Rascol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070774/publications.pdf>

Version: 2024-02-01

252
papers

29,837
citations

7069

78
h-index

5227

165
g-index

278
all docs

278
docs citations

278
times ranked

21511
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	2.2	18
2	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 65-73.	1.1	8
3	COMT Inhibitors in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2022, 36, 261-282.	2.7	18
4	A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1088-1093.	2.2	17
5	Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [¹⁸ F]-MPPF PET Study. <i>Movement Disorders</i> , 2021, 36, 246-251.	2.2	15
6	Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. <i>Movement Disorders</i> , 2021, 36, 750-757.	2.2	26
7	Broad white matter impairment in multiple system atrophy. <i>Human Brain Mapping</i> , 2021, 42, 357-366.	1.9	16
8	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. <i>Movement Disorders</i> , 2021, 36, 449-459.	2.2	16
9	Personality dimensions of patients can change during the course of parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245142.	1.1	5
10	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	1.1	39
11	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. <i>Movement Disorders</i> , 2021, 36, 1704-1711.	2.2	18
12	Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. <i>Journal of Parkinson's Disease</i> , 2021, 11, 421-429.	1.5	7
13	Opicapone for Parkinson's disease: clinical evidence and future perspectives. <i>Neurodegenerative Disease Management</i> , 2021, 11, 193-206.	1.2	1
14	A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 128-133.	1.1	22
15	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	2.2	16
16	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.	1.5	8
17	Safety and Tolerability of Active Immunotherapy Targeting α -Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1079-1089.	1.5	29
18	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1019-1033.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Amantadine in the treatment of Parkinson's disease and other movement disorders. <i>Lancet Neurology</i> , 2021, 20, 1048-1056.	4.9	67
20	Clinical Trials for in Parkinsonâ€™s. <i>Neuromethods</i> , 2021, , 109-135.	0.2	1
21	Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. <i>Neurology</i> , 2021, 97, e1994-e2006.	1.5	2
22	Utilization Patterns of Amantadine in Parkinsonâ€™s Disease Patients Enrolled in the French COPARK Study. <i>Drugs and Aging</i> , 2020, 37, 215-223.	1.3	11
23	The â€œLong and Winding Roadâ€• of the Diseaseâ€™ Modifying Effects of Levodopa Has Not Ended Yet. <i>Movement Disorders</i> , 2020, 35, 397-399.	2.2	6
24	Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 4-10.	1.1	26
25	Excessive buccal saliva in patients with Parkinsonâ€™s disease of the French COPARK cohort. <i>Journal of Neural Transmission</i> , 2020, 127, 1607-1617.	1.4	3
26	Therapeutic strategies for Parkinsonâ€™s disease: promising agents in early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1249-1267.	1.9	6
27	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
28	A Phase 1 Randomized Trial of Specific Active <sc>Î±â€•Synuclein</sc> Immunotherapies <sc>PD01A</sc> and <sc>PD03A</sc> in Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1957-1965.	2.2	53
29	Cerebrospinal Fluid Levels of Kininogenâ€•1 Indicate Early Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2101-2106.	2.2	16
30	Evaluation of Prescription Practices of Domperidone in Parkinsonâ€™s Disease: A Cross Sectional Study Among French Neurologists. <i>CNS Drugs</i> , 2020, 34, 1267-1274.	2.7	1
31	Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 30-33.	1.1	10
32	Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinsonâ€™s Disease Patients (PSYCHO-STIM). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1-9.	1.5	4
33	Î²-Adrenoceptor Drugs and Parkinsonâ€™s Disease: A Nationwide Nested Caseâ€™Control Study. <i>CNS Drugs</i> , 2020, 34, 763-772.	2.7	11
34	Challenges and Perspectives in the Management of Late-Stage Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S75-S83.	1.5	14
35	Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. <i>Neurobiology of Disease</i> , 2020, 139, 104813.	2.1	49
36	LRRK2 in Parkinson disease: challenges of clinical trials. <i>Nature Reviews Neurology</i> , 2020, 16, 97-107.	4.9	281

#	ARTICLE	IF	CITATIONS
37	Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. <i>Movement Disorders</i> , 2019, 34, 1663-1671.	2.2	30
38	Multiple System Atrophy: Recent Developments and Future Perspectives. <i>Movement Disorders</i> , 2019, 34, 1629-1642.	2.2	65
39	Safety Profile of Opicapone in the Management of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	1.5	25
40	Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 789-793.	1.4	2
41	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 226-234.	1.1	4
42	How to diagnose parkinsonian central pain?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 50-53.	1.1	22
43	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	1.1	9
44	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 635-645.	0.9	10
45	Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 199-203.	1.1	18
46	Reversible myoclonus ataxia encephalitis related to anti-GLUR1 autoantibodies. <i>Movement Disorders</i> , 2019, 34, 438-439.	2.2	7
47	CVT-301 for Parkinson's disease: dose and effect size issues. <i>Lancet Neurology</i> , The, 2019, 18, 128-130.	4.9	2
48	Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 51-56.	1.1	15
49	Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018, 125, 1237-1250.	1.4	61
50	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 600-608.	2.2	77
51	Iron as a therapeutic target for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 568-574.	2.2	94
52	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. <i>Lancet Neurology</i> , The, 2018, 17, 223-231.	4.9	105
53	Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease. <i>Neurophysiologie Clinique</i> , 2018, 48, 103-110.	1.0	17
54	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.5	40
56	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.5	23
57	Suggestive association between <i>OPRM1</i> and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1878-1886.	2.2	37
58	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1033-1034.	4.9	11
59	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1034.	4.9	16
60	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 804-822.	21.5	178
61	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	2.2	73
62	Tamoxifen and the risk of Parkinsonism: a case/non-case study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1181-1184.	0.8	9
63	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 558-570.	1.0	34
64	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 749-759.	4.9	203
65	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
66	Longitudinal analysis of impulse control disorders in Parkinson disease. <i>Neurology</i> , 2018, 91, e189-e201.	1.5	175
67	Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 99-103.	0.8	11
68	Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 791-796.	1.2	7
69	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	4.9	131
70	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	1.4	11
71	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	4.5	146
72	L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. <i>European Journal of Neurology</i> , 2017, 24, 1532-1538.	1.7	43

#	ARTICLE	IF	CITATIONS
73	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	2.2	11
74	An original pharmacoepidemiologicalâ€“pharmacodynamic method: application to antipsychoticâ€“induced movement disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 612-622.	1.1	29
75	Espresso Coffee for the Treatment of Somnolence in Parkinsonâ€™s Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	1.1	19
76	Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. <i>Movement Disorders</i> , 2016, 31, 325-334.	2.2	87
77	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Movement Disorders</i> , 2016, 31, 1049-1054.	2.2	28
78	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 852-861.	1.0	79
79	Pharmacological Insights into Levodopaâ€“induced Motor Fluctuations in Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 523-526.	0.8	1
80	Unmasking levodopa resistance in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1602-1609.	2.2	80
81	Longâ€“term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	2.2	45
82	Atropinic (Anticholinergic) Burden in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 632-636.	2.2	23
83	A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 1373-1380.	2.2	111
84	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. <i>CNS Drugs</i> , 2016, 30, 703-717.	2.7	40
85	The safety and efficacy of safinamide mesylate for the treatment of Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 245-258.	1.4	25
86	Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinsonâ€™s disease psychosis (PDP). <i>Parkinsonism and Related Disorders</i> , 2016, 22, e91-e92.	1.1	1
87	PANDA: Prolonged release oxycodone/naloxone (OXN PR) for severe Parkinsonâ€™s disease (PD)-related pain. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e101-e102.	1.1	0
88	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	2.6	333
89	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	4.9	219
90	What Strategy Should France Implement for H2020?. <i>Therapie</i> , 2015, 70, 103-109.	0.6	0

#	ARTICLE	IF	CITATIONS
91	New treatments for levodopa-induced motor complications. <i>Movement Disorders</i> , 2015, 30, 1451-1460.	2.2	95
92	Distinctive Features of NREM Parasomnia Behaviors in Parkinson's Disease and Multiple System Atrophy. <i>PLoS ONE</i> , 2015, 10, e0120973.	1.1	7
93	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	4.9	90
94	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 6-16.	0.8	24
95	Falls in ambulatory non-demented patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1447-1455.	1.4	55
96	Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. <i>Brain</i> , 2015, 138, 1271-1283.	3.7	51
97	Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1491.	4.5	80
98	Prolonged-release oxycodone/naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 1161-1170.	4.9	102
99	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 898.e1-898.e7.	1.2	46
100	Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1323-1329.	1.1	40
101	Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis. <i>Neurobiology of Aging</i> , 2015, 36, 424-433.	1.5	81
102	Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	0.6	51
103	Withdrawing amantadine in dyskinetic patients with Parkinson disease. <i>Neurology</i> , 2014, 82, 300-307.	1.5	122
104	Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 884.	4.5	241
105	A Cross-Sectional Study on Drug Use in Multiple System Atrophy. <i>CNS Drugs</i> , 2014, 28, 483-490.	2.7	9
106	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 351-360.	1.0	35
107	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 509-522.	0.5	3
108	Jejunal levodopa infusion in Parkinson's disease. <i>Lancet Neurology</i> , The, 2014, 13, 128-129.	4.9	4

#	ARTICLE	IF	CITATIONS
109	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. <i>Lancet, The</i> , 2014, 383, 1138-1146.	6.3	368
110	The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. <i>Movement Disorders</i> , 2014, 29, 1074-1079.	2.2	66
111	Can a new trial end controversy over when to use levodopa?. <i>Nature Reviews Neurology</i> , 2014, 10, 488-489.	4.9	1
112	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 947-956.	1.1	93
113	Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. <i>Neurobiology of Disease</i> , 2014, 67, 133-139.	2.1	28
114	Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome. <i>Integrative Medicine International</i> , 2014, 1, 32-43.	0.6	0
115	Orthostatic hypotension in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2013, 3, 363-377.	1.2	1
116	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.	1.8	128
117	Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 548-552.	1.1	62
118	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	2.2	374
119	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	2.2	122
120	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology, The</i> , 2013, 12, 264-274.	4.9	426
121	Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (open-of-1) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 416-421.	1.1	27
122	Extended-release carbidopa-levodopa in Parkinson's disease. <i>Lancet Neurology, The</i> , 2013, 12, 325-326.	4.9	7
123	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology, The</i> , 2013, 12, 747-755.	4.9	175
124	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	2.2	59
125	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 81-95.	1.0	20
126	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	2.2	76

#	ARTICLE	IF	CITATIONS
127	Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 261-265.	0.2	85
128	Perampanel in Parkinson Disease Fluctuations. <i>Clinical Neuropharmacology</i> , 2012, 35, 15-20.	0.2	50
129	Drugs Associated With Restless Legs Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 824-827.	0.7	29
130	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-â€œUndertreated Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 174-181.	0.2	30
131	Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 589-596.	4.9	150
132	Assessment of quality of life with the multiple system atrophy healthâ€œrelated quality of life scale. <i>Movement Disorders</i> , 2012, 27, 1574-1577.	2.2	14
133	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	2.2	18
134	Assessment of the Scopa-Aut questionnaire in multiple system atrophy: Relation to UMSARS scores and progression over time. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 612-615.	1.1	24
135	Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 501-505.	1.1	54
136	A proofâ€œofâ€œconcept, randomized, placeboâ€œcontrolled, multiple crossâ€œovers (nâ€œofâ€œ1) study of naftazone in Parkinsonâ€œs disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 557-564.	1.0	27
137	Serotonin reuptake inhibitors for depression in PD. <i>Nature Reviews Neurology</i> , 2012, 8, 365-366.	4.9	10
138	Do Parkinsonâ€œs disease patients disclose their adverse events spontaneously?. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 857-865.	0.8	23
139	Perampanel, an AMPA antagonist, found to have no benefit in reducing â€œoffâ€œ-time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.	2.2	68
140	Influence of Age, Circadian and Homeostatic Processes on Inhibitory Motor Control: A Go/Nogo Task Study. <i>PLoS ONE</i> , 2012, 7, e39410.	1.1	51
141	Priorities in Parkinson's disease research. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 377-393.	21.5	364
142	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	4.9	192
143	Pramipexole for the treatment of early Parkinsonâ€œs disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 925-935.	1.4	19
144	Pardoprunox in early Parkinson's disease: Results from 2 large, randomized doubleâ€œblind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	2.2	38

#	ARTICLE	IF	CITATIONS
145	Milestones in Parkinson's disease therapeutics. <i>Movement Disorders</i> , 2011, 26, 1072-1082.	2.2	162
146	The <i>Movement Disorders</i> task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Movement Disorders</i> , 2011, 26, 1985-1992.	2.2	52
147	Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. <i>Movement Disorders</i> , 2011, 26, 2226-2231.	2.2	122
148	The <i>Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</i> . <i>Movement Disorders</i> , 2011, 26, S2-41.	2.2	479
149	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. <i>Brain</i> , 2011, 134, 856-862.	3.7	66
150	Safety of rasagiline for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 633-643.	1.0	25
151	Thought disorders among non-demented outpatients with Parkinson's disease: prevalence and associated factors. <i>Journal of Neural Transmission</i> , 2010, 117, 1183-1188.	1.4	4
152	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 573-580.	4.9	476
153	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
154	Skin cancer and Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 139-148.	2.2	43
155	Orodispersible sublingual priribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, crossover study. <i>Movement Disorders</i> , 2010, 25, 368-376.	2.2	21
156	Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	2.2	32
157	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010, 25, 896-905.	2.2	63
158	Fatigue rating scales critique and recommendations by the <i>Movement Disorders Society</i> task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 805-822.	2.2	193
159	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	2.2	90
160	Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study. <i>Movement Disorders</i> , 2010, 25, 1627-1632.	2.2	38
161	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	2.2	214
162	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	2.2	205

#	ARTICLE	IF	CITATIONS
163	Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database. <i>Movement Disorders</i> , 2010, 25, 1876-1880.	2.2	19
164	Efficacy, safety, and tolerability of overnight switching from immediate to once daily extended release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2326-2332.	2.2	36
165	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2542-2549.	2.2	87
166	Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2221-2230.	0.9	8
167	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	3.7	374
168	Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 941-968.	2.7	96
169	Volume and iron content in basal ganglia and thalamus. <i>Human Brain Mapping</i> , 2009, 30, 2667-2675.	1.9	98
170	¹²³ I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2009, 24, S732-41.	2.2	95
171	Contrasting Changes in Cortical Activation Induced by Acute High-Frequency Stimulation within the Globus Pallidus in Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 235-243.	2.4	17
172	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	13.9	830
173	Object naming and action-verb generation in Parkinson's disease: A fMRI study. <i>Cortex</i> , 2009, 45, 960-971.	1.1	103
174	Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2009, 279, 76-79.	0.3	20
175	Rotigotine transdermal delivery for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 677-691.	0.9	41
176	Confinement and Sleep Deprivation Effects on Propensity to Take Risks. <i>Aviation, Space, and Environmental Medicine</i> , 2009, 80, 73-80.	0.6	34
177	Rotigotine for the Treatment of Advanced Parkinson's Disease. <i>European Neurological Review</i> , 2009, 4, 24.	0.5	0
178	Placebo influences on dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 700-707.	2.2	111
179	Chronic pain in Parkinson's disease: The cross-sectional French DoPaMiP survey. <i>Movement Disorders</i> , 2008, 23, 1361-1369.	2.2	257
180	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796

#	ARTICLE	IF	CITATIONS
181	Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations. <i>Archives of Neurology</i> , 2008, 65, 577.	4.9	32
182	Dopamine agonists. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 73-92.	1.0	6
183	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	2.2	1,097
184	Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007, 22, 179-186.	2.2	249
185	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	2.2	583
186	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2007, 22, 1138-1144.	2.2	66
187	Skin cancers and precancerous lesions in Parkinson's disease patients. <i>Movement Disorders</i> , 2007, 22, 1471-1475.	2.2	18
188	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	2.2	221
189	Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 513-520.	4.9	359
190	Methylphenidate modulates cerebral post-stroke reorganization. <i>NeuroImage</i> , 2006, 33, 913-922.	2.1	49
191	Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need. <i>Movement Disorders</i> , 2006, 21, 1059-1061.	2.2	31
192	Early priribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. <i>Movement Disorders</i> , 2006, 21, 2110-2115.	2.2	61
193	Pergolide. <i>Clinical Neuropharmacology</i> , 2005, 28, 120-125.	0.2	14
194	Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. <i>NeuroImage</i> , 2005, 27, 299-313.	2.1	72
195	Rasagiline in the pharmacotherapy of Parkinson's disease – a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2061-2075.	0.9	28
196	Subthalamic Nucleus Stimulation Reduces Abnormal Motor Cortical Overactivity in Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1307-13.	4.9	104
197	Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study. <i>Movement Disorders</i> , 2004, 19, 83-90.	2.2	30
198	Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. <i>Movement Disorders</i> , 2004, 19, 1006-1011.	2.2	15

#	ARTICLE	IF	CITATIONS
199	MovementDisorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations TheMovementDisorder Society Task Force on rating scales for Parkinson's disease. Movement Disorders, 2004, 19, 1020-1028.	2.2	1,739
200	Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2004, 19, 997-1005.	2.2	331
201	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Movement Disorders, 2004, 19, 1391-1402.	2.2	481
202	Dopaminagonists and fibrotic valvular heart disease: Further considerations. Movement Disorders, 2004, 19, 1524-1525.	2.2	19
203	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). Clinical Neuropharmacology, 2004, 27, 58-62.	0.2	161
204	Monoamine oxidase inhibitorsâ€”is it time to up the TEMPO?. Lancet Neurology, The, 2003, 2, 142-143.	4.9	10
205	Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study. Movement Disorders, 2003, 18, 418-425.	2.2	50
206	Clinical and economic analysis of spa therapy in Parkinson's disease. Movement Disorders, 2003, 18, 578-584.	2.2	37
207	Limitations of current Parkinson's disease therapy. Annals of Neurology, 2003, 53, S3-S15.	2.8	250
208	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 2003, 54, 93-101.	2.8	820
209	How much phenotypic variation can be attributed toparkingenotype?. Annals of Neurology, 2003, 54, 176-185.	2.8	271
210	Hereditary ferritinopathy. Journal of the Neurological Sciences, 2003, 207, 110-111.	0.3	34
211	Young-Onset Parkinson Disease With and Without Parkin Gene Mutations. Archives of Neurology, 2003, 60, 713.	4.9	35
212	The management of patients with early Parkinson's disease. Advances in Neurology, 2003, 91, 203-11.	0.8	4
213	Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet, The, 2002, 359, 1589-1598.	6.3	266
214	A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects. NeuroImage, 2002, 15, 26-36.	2.1	107
215	Clinical Features and Disease Haplotypes of Individuals With the N279K tau Gene Mutation. Archives of Neurology, 2002, 59, 943.	4.9	39
216	Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia, 2002, 40, 1815-1821.	0.7	47

#	ARTICLE	IF	CITATIONS
217	Orthostatic Hypotension in Patients with Parkinson's Disease. <i>Drugs and Aging</i> , 2001, 18, 495-505.	1.3	115
218	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 181-183.	0.2	85
219	Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia. <i>Clinical Neuropharmacology</i> , 2001, 24, 313-323.	0.2	45
220	Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. <i>Journal of Neurology</i> , 2001, 248, 426-427.	1.8	44
221	Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. <i>Annals of Neurology</i> , 2001, 50, 718-729.	2.8	345
222	Within-Session and Between-Session Reproducibility of Cerebral Sensorimotor Activation: A Test-Retest Effect Evidenced with Functional Magnetic Resonance Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 592-607.	2.4	145
223	Stratégies pharmacothérapeutiques actuelles et futures dans la prise en charge de la maladie de Parkinson. <i>Disease Management and Health Outcomes</i> , 2001, 9, 31-39.	0.3	1
224	Adverse Drug Reactions to Selegiline [colon] A Review of the French Pharmacovigilance Database. <i>Clinical Neuropharmacology</i> , 2000, 23, 271-275.	0.2	43
225	A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis. <i>Clinical Neuropharmacology</i> , 2000, 23, 203-207.	0.2	23
226	Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2000, 13, 431-436.	1.8	13
227	Neural Substrate for the Effects of Passive Training on Sensorimotor Cortical Representation: A Study with Functional Magnetic Resonance Imaging in Healthy Subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 478-484.	2.4	153
228	Mapping of Spinocerebellar Ataxia 13 to Chromosome 19q13.3-q13.4 in a Family with Autosomal Dominant Cerebellar Ataxia and Mental Retardation. <i>American Journal of Human Genetics</i> , 2000, 67, 229-235.	2.6	166
229	Continuous dopamine-receptor stimulation in early Parkinson's disease. <i>Trends in Neurosciences</i> , 2000, 23, S117-S126.	4.2	185
230	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	13.9	1,467
231	Cerebral Functional Magnetic Resonance Imaging Activation Modulated by a Single Dose of the Monoamine Neurotransmission Enhancers Fluoxetine and Fenozolone during Hand Sensorimotor Tasks. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1365-1375.	2.4	70
232	A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. <i>Acta Neuropathologica</i> , 1999, 98, 62-77.	3.9	174
233	A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 336-341.	2.2	30
234	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. <i>Movement Disorders</i> , 1998, 13, 39-45.	2.2	262

#	ARTICLE	IF	CITATIONS
235	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. <i>Movement Disorders</i> , 1998, 13, 46-51.	2.2	135
236	Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. <i>Movement Disorders</i> , 1998, 13, 673-676.	2.2	36
237	??2-Adrenoceptor Antagonists. <i>CNS Drugs</i> , 1998, 10, 189-207.	2.7	39
238	A study of tolerance to apomorphine. <i>British Journal of Pharmacology</i> , 1996, 117, 781-786.	2.7	23
239	New Directions in the Drug Treatment of Parkinson's Disease. <i>Drugs and Aging</i> , 1996, 9, 169-184.	1.3	12
240	A Study of Dopaminergic Sensitivity in Parkinson's Disease: Comparison in "De Novo" and Levodopa-Treated Patients. <i>Clinical Neuropharmacology</i> , 1996, 19, 420-427.	0.2	11
241	Antivertigo Medications and Drug-Induced Vertigo. <i>Drugs</i> , 1995, 50, 777-791.	4.9	96
242	Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. <i>Movement Disorders</i> , 1994, 9, 437-440.	2.2	78
243	Effect of Side and Rate of Stimulation on Cerebral Blood Flow Changes in Motor Areas during Finger Movements in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 639-645.	2.4	83
244	Supplementary and Primary Sensory Motor Area Activity in Parkinson's Disease. <i>Archives of Neurology</i> , 1992, 49, 144.	4.9	222
245	Parkinson's disease and weight loss: A study with anthropometric and nutritional assessment. <i>Clinical Autonomic Research</i> , 1992, 2, 153-157.	1.4	66
246	Migraine Attacks Induced by Subcutaneous Apomorphine in Two Migrainous Parkinsonian Patients. <i>Clinical Neuropharmacology</i> , 1990, 13, 264-267.	0.2	12
247	Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release. <i>British Journal of Pharmacology</i> , 1990, 100, 471-476.	2.7	14
248	Involvement of a pertussis toxin-sensitive G α protein in the pharmacological properties of septohippocampal neurones. <i>British Journal of Pharmacology</i> , 1989, 96, 956-960.	2.7	8
249	β 2-Adrenergic Sensitivity in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 138-144.	0.2	17
250	A Pilot Study of Stiripentol, a new Anticonvulsant Drug, in Complex Partial Seizures Uncontrolled by Carbamazepine. <i>Clinical Neuropharmacology</i> , 1989, 12, 119-123.	0.2	19
251	Lack of Correlation Between Plasma Levels of Amitriptyline (and Nortriptyline) and Clinical Improvement of Chronic Pain of Peripheral Neurologic Origin. <i>Clinical Neuropharmacology</i> , 1987, 10, 560-564.	0.2	9
252	Adrenal Catecholamine Concentration After Domperidone. <i>Clinical Neuropharmacology</i> , 1987, 10, 479-481.	0.2	3